BACKGROUND: Antibody titers to influenza hemagglutinin (HA) and neuraminidase (NA) surface antigens increase in the weeks after infection or vaccination, and decrease over time thereafter. However, the rate of decline has been debated. METHODS:Healthy adults participating in a randomizedplacebo-controlled trial of inactivated (IIV) and live-attenuated (LAIV) influenza vaccines provided blood specimens immediately prior to vaccination and at 1, 6, 12, and 18 months postvaccination. Approximately half had also been vaccinated in the prior year. Rates of hemagglutination inhibition (HAI) and neuraminidase inhibition (NAI) titer decline in the absence of infection were estimated. RESULTS:HAI and NAI titers decreased slowly over 18 months; overall, a 2-fold decrease in antibody titer was estimated to take >600 days for all HA and NA targets. Rates of decline were fastest among IIV recipients, explained in part by faster declines with higher peak postvaccination titer. IIV and LAIV recipients vaccinated 2 consecutive years exhibited significantly lower HAI titers following vaccination in the second year, but rates of persistence were similar. CONCLUSIONS: Antibody titers to influenza HA and NA antigens may persist over multiple seasons; however, antigenic drift of circulating viruses may still necessitate annual vaccination. Vaccine seroresponse may be impaired with repeated vaccination.
RCT Entities:
BACKGROUND: Antibody titers to influenza hemagglutinin (HA) and neuraminidase (NA) surface antigens increase in the weeks after infection or vaccination, and decrease over time thereafter. However, the rate of decline has been debated. METHODS: Healthy adults participating in a randomized placebo-controlled trial of inactivated (IIV) and live-attenuated (LAIV) influenza vaccines provided blood specimens immediately prior to vaccination and at 1, 6, 12, and 18 months postvaccination. Approximately half had also been vaccinated in the prior year. Rates of hemagglutination inhibition (HAI) and neuraminidase inhibition (NAI) titer decline in the absence of infection were estimated. RESULTS: HAI and NAI titers decreased slowly over 18 months; overall, a 2-fold decrease in antibody titer was estimated to take >600 days for all HA and NA targets. Rates of decline were fastest among IIV recipients, explained in part by faster declines with higher peak postvaccination titer. IIV and LAIV recipients vaccinated 2 consecutive years exhibited significantly lower HAI titers following vaccination in the second year, but rates of persistence were similar. CONCLUSIONS: Antibody titers to influenza HA and NA antigens may persist over multiple seasons; however, antigenic drift of circulating viruses may still necessitate annual vaccination. Vaccine seroresponse may be impaired with repeated vaccination.
Authors: Arnold S Monto; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Merry Liu; Weimin Zhong; Min Levine; Jacqueline M Katz; Suzanne E Ohmit Journal: J Infect Dis Date: 2015-04-08 Impact factor: 5.226
Authors: Mark G Thompson; De-Kun Li; Pat Shifflett; Leslie Z Sokolow; Jeannette R Ferber; Samantha Kurosky; Sam Bozeman; Sue B Reynolds; Roxana Odouli; Michelle L Henninger; Tia L Kauffman; Lyndsay A Avalos; Sarah Ball; Jennifer L Williams; Stephanie A Irving; David K Shay; Allison L Naleway Journal: Clin Infect Dis Date: 2013-11-26 Impact factor: 9.079
Authors: Anthony E Fiore; David K Shay; Penina Haber; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox Journal: MMWR Recomm Rep Date: 2007-07-13
Authors: Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg Journal: PLoS One Date: 2008-08-20 Impact factor: 3.240
Authors: Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Suzana Sabaiduc; Alireza Eshaghi; James A Dickinson; Kevin Fonseca; Anne-Luise Winter; Jonathan B Gubbay; Mel Krajden; Martin Petric; Hugues Charest; Nathalie Bastien; Trijntje L Kwindt; Salaheddin M Mahmud; Paul Van Caeseele; Yan Li Journal: PLoS One Date: 2014-03-25 Impact factor: 3.240
Authors: Shuo Feng; Susan S Chiu; Eunice L Y Chan; Mike Y W Kwan; Joshua S C Wong; Chi-Wai Leung; Yiu Chung Lau; Sheena G Sullivan; J S Malik Peiris; Benjamin J Cowling Journal: Lancet Respir Med Date: 2018-11-12 Impact factor: 30.700
Authors: Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto Journal: Vaccine Date: 2019-02-07 Impact factor: 3.641
Authors: Alaina J Mooney; Jon D Gabbard; Zhuo Li; Daniel A Dlugolenski; Scott K Johnson; Ralph A Tripp; Biao He; S Mark Tompkins Journal: J Virol Date: 2017-11-14 Impact factor: 5.103
Authors: Li Wang; Timothy Z Chang; Yuan He; Jong R Kim; Shelly Wang; Teena Mohan; Zachary Berman; S Mark Tompkins; Ralph A Tripp; Richard W Compans; Julie A Champion; Bao-Zhong Wang Journal: Nanomedicine Date: 2016-09-10 Impact factor: 5.307